Patents Issued in October 3, 2017
-
Patent number: 9775861Abstract: An ophthalmic composition of water soluble ingredients provides additional moisture to the eye by promoting moisture absorption from the air and providing long lasting relief. The composition can include two groups of ingredients, one a liquid and the other a solid. Together, the ingredients form a substance that ranges from a liquid to a gel. Benefits of such composition include longer lasting symptom relief with less applications and increased moisture production.Type: GrantFiled: September 24, 2015Date of Patent: October 3, 2017Inventors: Paul S. Jensen, Isaiah U. Lieberman
-
Patent number: 9775862Abstract: A method of enhancing the binding of growth factors and cell cultures to a demineralized allograft bone material which includes applying ex vivo an effective quantity of an ionic force change agent to at least a portion of the surface of a demineralized allograft bone material to produce a binding-sensitized demineralized allograft bone material and implanting the binding-sensitized demineralized allograft bone material into a host bone. The ionic force change agent may include at least one of enzymes, pressure, chemicals, heat, sheer force, oxygen plasma, supercritical nitrogen, supercritical carbon, supercritical water or a combination thereof. A molecule, a cell culture, or a combination thereof is administered to the binding-sensitized demineralized allograft bone material.Type: GrantFiled: January 30, 2012Date of Patent: October 3, 2017Assignee: Warsaw Orthopedic, Inc.Inventors: Guobao Wei, Susan J. Drapeau
-
Patent number: 9775863Abstract: A method of treating liver-based inborn, metabolic deficiencies is disclosed by treatment of an individual, such as a patient suffering from liver-based inborn, metabolic deficiencies, with human progenitor or stem cells, a cell population or their progeny. The cells used in the treatment have the following characteristics. They are positive for vimentin, ?-smooth muscle actin (ASMA), and for at least one mesenchymal marker such as CD90, CD29, CD73, and CD44. They are positive for at least one hepatocyte marker such as albumin, alpha-fetoprotein, alpha-1 antitrypsin, HNF-4 and MRP2 transporter. They express at least one hepatocyte-like property or function such as G6P, CYP1B1, CYP3A4, TDO, TAT, GS, GGT, CK8, and EAAT2. They are negative for at least one marker such as cytokeratin-19, CD45, CD34, CD49f, CD133, HLA-DR, and CD117. They have mesenchymal-like morphology. They originate from human adult liver cells.Type: GrantFiled: July 9, 2015Date of Patent: October 3, 2017Assignee: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Etienne Sokal, Mustapha Najimi
-
Patent number: 9775864Abstract: The invention provides methods for the treatment of vaginal laxity which include delivering a cell-containing composition to the vagina. The composition can include fat tissue to provide a bulking effect to reduce the size of the vaginal opening. The cells can provide healing and revascularization of the vaginal treatment area to sustain the bulking provided by the fat. The invention also provides systems and compositions useful for performing the method, and can include instruments and devices for removal of autologous adipose tissue from a patient (e.g., by liposuction), equipment for the enrichment of cells from adipose tissue, mechanical processing of adipose tissue, and the mixing of cells and processed adipose tissue. Devices for the delivery of the cell compositions to the vagina can also be included in the system.Type: GrantFiled: January 31, 2014Date of Patent: October 3, 2017Inventor: David J. Yonce
-
Patent number: 9775865Abstract: Systems, kits and methods are provided, which analyze the large intestine content and utilize acoustic signals detected during delivery of water into the large intestine and drained large intestine contents to derive large intestine characteristics such as microbiotal analysis. Systems may include a water delivery unit including a water supply and a nozzle connected thereto, configured to introduce water controllably into a patient's large intestine, and an analysis unit that provides information about the drained contents using optical examination or biological assays. The information may be related to acoustic analysis of signals from acoustic sensors that are attachable to a patient's abdomen. A variety of sensor configurations, positioning options, analysis strategies and large intestine characteristics are presented.Type: GrantFiled: April 26, 2016Date of Patent: October 3, 2017Assignee: HYGIEACARE, Inc.Inventors: Gavriel David Meron, Mordechai Yehuda Frisch
-
Patent number: 9775866Abstract: Microcapsules are described that comprise (a) a liquid aqueous or hydrogel core; (b) a semipermeable membrane surrounding said core; (c) live animal cells (e.g., pancreatic cells) in the core; and (d) oxygen-generating particles in said core, said oxygen-generating particles included in said microcapsules in an amount sufficient to lengthen the duration of viability of said animal cells in said microcapsules. Compositions comprising such microcapsules and uses thereof, such as in treating diabetes, are also described.Type: GrantFiled: January 20, 2017Date of Patent: October 3, 2017Assignee: Wake Forest University Health SciencesInventors: Emmanuel C. Opara, Benjamin S. Harrison
-
Patent number: 9775867Abstract: There is provided an isolated E. coli strain deposited at the International Depositary Authority of Canada (IDAC) on Jun. 20, 2013 and attributed accession number 200613-01. There is also provided methods of using this strain for preventing edema disease or diarrhea caused by an F18 pathogenic E. coli infection in an animal.Type: GrantFiled: August 25, 2016Date of Patent: October 3, 2017Assignee: PREVTEC MICROBIA INC.Inventors: John Morris Fairbrother, Éric Nadeau, Clarisse Desautels
-
Patent number: 9775868Abstract: The present invention relates to a traditional Chinese medicine composition for regulating immunity and preparation method thereof, characterized in that the composition comprises raw materials such as Radix Panacis Quinquefolii, Ganoderma, fermented Cordyceps sinensis powder, Flos Rosae Rugosae, and Rhizoma Anemarrhenae and is prepared into various conventional pharmaceutical formulations through processes such as pulverization, water decoction and alcohol extraction. The traditional Chinese medicine composition is effective in preventing and treating allergic diseases, hepatitis B and AIDS, elevating leukocytes, preventing and treating radiation injury, reducing toxic and side effects resulting from radiotherapy and chemotherapy, improving the male sexual function, enhancing immunity of the human body and alleviating physical fatigue.Type: GrantFiled: September 22, 2013Date of Patent: October 3, 2017Assignee: JIANGZHONG PHARMACEUTICAL CO., LTD.Inventors: Hongguang Zhong, Minzhi Yi, Jianzhong Lu
-
Patent number: 9775869Abstract: A composition having an extract of seed of Emblica officinalis. Methods of preparing extract of seed of Emblica officinalis. An amla seed blend composition having various ratios of extracts of seeds of Emblica officinalis. Nutraceutical or pharmaceutical methods for decreasing the total cholesterol, decreasing triglyceride, decreasing blood glucose level, enhancing HDL-C levels, increasing the HDL-C level to total cholesterol ratio, lowering LDL-C levels, decreasing the CRP level, decreasing the intima media thickening, reducing hair fall in mammals especially human beings. The extract of seed of Emblica officinalis, or the amla seed blend composition is more effective compared to extracts prepared from fruits of Emblica officinalis.Type: GrantFiled: May 26, 2015Date of Patent: October 3, 2017Inventor: Benny Antony
-
Patent number: 9775870Abstract: The present invention relates to an extract of a processed herbal medicinal plant and a composition for skin external application which contains the extract. More specifically, the composition for skin external application contains an extract of processed herbal medicinal plant, prepared through a method comprising the steps of: (a) processing an herbal medicinal plant by a process of boiling, steaming, roasting, baking or heating the medicinal plant or a combination of two or more of these processes; (b) obtaining an extract of the processed medicinal plant. The composition shows an improved antioxidant effect.Type: GrantFiled: April 7, 2016Date of Patent: October 3, 2017Assignee: AMOREPACIFIC CORPORATIONInventors: Jun Seong Park, Hye Yoon Park, Dong Hyun Kim, Eun Jeong Moon, Ji Hye Chung, Jae Kyoung Lee, Duck Hee Kim, Han Kon Kim
-
Patent number: 9775871Abstract: Herbal compositions and their use in the prevention and/or treatment of hepatitis are provided The herbal compositions comprise an extract of flowers, leaves, and roots from the plant genera Cordia, Annona, and Curcuma, respectively, wherein the specific species are Cordia lutea, Annona muricata and Curcuma longa.Type: GrantFiled: October 3, 2008Date of Patent: October 3, 2017Assignees: SABELL CORPORATIONInventor: Jose Gonzalo Cabanillas Coral
-
Patent number: 9775872Abstract: The present disclosure refers to topical pharmaceutical bases that possess antiviral properties. Further, these topical pharmaceutical bases are employed for preventing a patient to be infected by viral diseases. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective antiviral treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve antiviral effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for preventing viral diseases.Type: GrantFiled: August 20, 2015Date of Patent: October 3, 2017Assignee: Professional Compounding Centers of AmericaInventor: Daniel Banov
-
Patent number: 9775873Abstract: The present disclosure relates to compositions and related methods to reduce body weight, body fat, waist and hip size, plasma total cholesterol, LDL, triglycerides, blood glucose, leptin and C-reactive protein levels and increase in HDL and serotonin levels in an mammal. The LeptiCore® formulation disclosed, at both the low and high dosages, is helpful in the management of fat gain and its related complications. The higher dosage resulted in significantly greater reductions in body weight and triglyceride, blood glucose, and C-reactive protein levels, as well as increased serotonin levels.Type: GrantFiled: April 1, 2014Date of Patent: October 3, 2017Inventor: Julius Enyoug Oben
-
Patent number: 9775874Abstract: In a new supplemental combination and method of treatment, the herbs Vitex agnus-castus (chasteberry), green tea, and arginine treat premenstrual syndrome, premenstrual tension, as an alternative to conventional women's hormone replacement therapy, and to offset the problems related to sub-optimal hormone balance or decline resulting from age, genetics, stress, or environmental influences. Furthermore, the combination may be enhanced with a phytoestrogen and/or a progesterone-receptor enhancing agent.Type: GrantFiled: September 30, 2013Date of Patent: October 3, 2017Assignee: The Daily Wellness CompanyInventor: Denny W. Kwock
-
Patent number: 9775875Abstract: The invention discloses a method of processing Zingiber zerumbet for producing a processed sample of Zingiber zerumbet, which easily releases flavonoids in a following extraction process. The method includes the steps of: soaking a raw sample of Zingiber zerumbet with a processing reagent selected from rice vinegar or yellow wine at 23-27° C. for 20-28 hours; and steaming the soaked product at 0.6-1.4 kg/cm2, 80-120° C. for 20-40 minutes.Type: GrantFiled: May 29, 2015Date of Patent: October 3, 2017Assignee: HAN SHENG PHARMTECH, INC.Inventors: Shorong-Shii Liou, I-Min Liu, Cheng Yang, Sheng-Da Lin, Chi-Da Fang, Bo-Wei Lin, Wan-Ling Huang, Ya-Ting Shiu
-
Patent number: 9775876Abstract: Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with these embodiments, compositions that inhibit autonomous CaMKII activity may be used for treating conditions causing neuronal cell death, for treating cancer or for treating neurodegenerative disorders.Type: GrantFiled: September 17, 2015Date of Patent: October 3, 2017Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporateInventors: K. Ulrich Bayer, Steve Coultrap
-
Patent number: 9775877Abstract: A novel combination comprising a ?-hairpin peptidomimetic of the formula cyclo(-Thr-Trp-Ile-Dab-Orn-DDab-Dab-Trp-Dab-Dab-Ala-Ser-DPro-Pro) (I), and a compound of the glycylcycline class, especially tigecycline, that enable therapeutic control of specific bacterial infections in human or animals at doses of the individual compounds lower than either of the compounds administered alone. The combination can be used as a medicament to treat e.g. skin or soft tissue infections; eye, ear, blood stream, or intra-abdominal infections; infections related to respiratory diseases, to bone diseases, to cardiovascular diseases, to genitourinal diseases, or to gastrointestinal diseases.Type: GrantFiled: August 7, 2013Date of Patent: October 3, 2017Assignee: POLYPHOR AGInventors: Glenn E. Dale, Daniel Obrecht, Francesca Bernardini
-
Patent number: 9775878Abstract: Methods of treating bacterial infections in a subject using a synergistic combination of oritavancin and a polymyxin are disclosed.Type: GrantFiled: August 28, 2014Date of Patent: October 3, 2017Assignee: THE MEDICINES COMPANYInventors: Gregory Moeck, Francis Arhin
-
Patent number: 9775879Abstract: The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPAR?2 to induce the formation of a complex of HDAC3 and PPAR?2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPAR?2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor.Type: GrantFiled: April 30, 2014Date of Patent: October 3, 2017Assignee: Korea University Research and Business FoundationInventors: Je Sang Ko, Jeong-Han Kim
-
Patent number: 9775880Abstract: The present invention relates to a composition which comprises the following myelin basic protein peptides: MBP 30-44; MBP 83-99; MBP 131-145; and MBP 140-154. The composition may be used to treat a disease, in particular multiple sclerosis and/or optical neuritis and the invention also relates to such uses and methods.Type: GrantFiled: June 3, 2016Date of Patent: October 3, 2017Assignee: APITOPE TECHNOLOGY (BRISTOL) LIMITEDInventors: David Wraith, Heather Streeter
-
Patent number: 9775881Abstract: Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.Type: GrantFiled: May 22, 2014Date of Patent: October 3, 2017Assignees: Five Prime Therapeutics, Inc., GlaxoSmithKline Intellectual Property (No.2) LimitedInventors: David Bellovin, Kevin Baker, Thomas Brennan, Arundathy Nirmalini Pandite, Bijoyesh Mookerjee, Maurice P. DeYoung, Rakesh Kumar
-
Patent number: 9775882Abstract: Medical devices and methods including polymers having biologically active agents therein are disclosed. The medical devices can be useful as implantable devices such as orthopedic implants.Type: GrantFiled: September 19, 2008Date of Patent: October 3, 2017Assignee: Medtronic, Inc.Inventors: Phillip Edward McDonald, Christopher M. Hobot
-
Patent number: 9775883Abstract: Without limitation, some embodiments comprise a method of treatment for promoting recovery of peripheral neuropathy in a subject, including administering to a subject in need of such treatment a therapeutically effective amount of a composition comprised of thymosin beta 4, amino acid sequences LKKTET or LKKTNT, and/or any conservative variants thereof, or an agent that stimulates production of any of those materials, or a conservative variant thereof.Type: GrantFiled: December 21, 2012Date of Patent: October 3, 2017Assignee: Henry Ford Health SystemInventors: Michael Chopp, Zhenggang Zhang, Daniel C. Morris, Lei Wang
-
Patent number: 9775884Abstract: A fibrinogen preparation is provided which has an improved solubility, may be prepared within a short time and may be used rapidly in clinical set-up. A solid fibrinogen preparation comprising as a main ingredient fibrinogen and further containing the following components: albumin; a nonionic surfactant; a basic amino acid or a salt thereof; and at least two amino acids or a salt thereof selected from an acidic amino acid or a salt thereof and a neutral amino acid or a salt thereof. The solid fibrinogen composition of the present invention may be held on a medical material to form a supporting material holding fibrinogen. Besides, the supporting material holding fibrinogen may be combined with a component comprising as a main ingredient thrombin to provide a fibrin adhesive.Type: GrantFiled: March 21, 2008Date of Patent: October 3, 2017Assignee: The Chemo-Sero-Therapeutic Research InstituteInventors: Shinichi Miyagawa, Tatsuya Araki, Tsutomu Hamuro, Mika Okuda, Hiroshi Kaetsu
-
Patent number: 9775885Abstract: The present invention relates to a method for treating a bone loss disease, condition, or disorder in a subject in need thereof, comprising administering to said subject a pharmaceutically effective amount of a composition comprising thrombomodulin lectin-like domain (TMD1).Type: GrantFiled: January 25, 2017Date of Patent: October 3, 2017Assignee: KAOHSIUNG MEDICAL UNIVERISTYInventors: Tsung-Lin Cheng, Jwu-Lai Yeh, Mei-Ling Ho, Guey-Yueh Shi, Hua-Lin Wu
-
Patent number: 9775886Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.Type: GrantFiled: September 11, 2012Date of Patent: October 3, 2017Assignee: Celularity, Inc.Inventors: Mohit Bhatia, Chris Lugo, Qian Ye, James W. Edinger
-
Patent number: 9775887Abstract: Disclosed is a formulation of the following enzymes: Beta Glucanase, Chymotrypsin, Phytase, Lactase, and Invertase, which has been found to be effective in treating salicylate intolerant people, and causing a significant improvement in a wide variety of pathologies and symptoms, including, but not limited to: stuttering, migraines, ADHD, behavioral deficits, Tourettes disease, seizures, autism (ASD), atrial fibrillation, anxiety, depression, joint pain, cognitive and perceptual disorders, respiratory difficulties and non-diabetic neuropathy.Type: GrantFiled: December 14, 2015Date of Patent: October 3, 2017Inventor: Thea Fournier
-
Patent number: 9775888Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.Type: GrantFiled: April 2, 2013Date of Patent: October 3, 2017Assignee: ALBUMEDIX A/SInventors: David J. Ballance, Darrell Sleep
-
Patent number: 9775889Abstract: Methods and combinations are provided for controlling the duration of action, in vivo, of matrix-degrading enzymes. The methods and combinations permit temporary in-vivo activation of matrix-degrading enzymes upon administration to the extra cellular matrix (or “ECM”). Matrix-degrading enzymes having a controlled duration of action can be used to treat ECM-mediated diseases or disorders characterized by increased deposition or accumulation of one or more ECM components.Type: GrantFiled: April 2, 2014Date of Patent: October 3, 2017Assignee: Halozyme, Inc.Inventors: Gilbert Keller, Gregory I. Frost
-
Patent number: 9775890Abstract: The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one factor Xa inhibitor, preferably rivaroxaban, as well as at least one thrombin inhibitor, preferably bivalirudin.Type: GrantFiled: June 15, 2012Date of Patent: October 3, 2017Assignee: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Xavier Stephenne, Etienne Sokal, Mustapha Najimi, Stéphane Eeckhoudt, Cédric Hermans
-
Patent number: 9775891Abstract: The present invention relates to methods of inducing a T-cell response against a EGFRvIII in a subject. These method comprise administering to a subject a composition which expresses at least one immunogenic polypeptide, the amino acid sequence of which comprise a plurality of EGFRvIII polypeptide sequences, the sequence of which each comprise EEKKGNYV (SEQ ID NO: 3), and/or administering the polypeptide itself.Type: GrantFiled: November 25, 2015Date of Patent: October 3, 2017Assignees: ADURO BIOTECH, INC., PROVIDENCE HEALTH & SERVICES—OREGONInventors: Peter M. Lauer, Keith Bahjat
-
Patent number: 9775892Abstract: There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.Type: GrantFiled: December 9, 2014Date of Patent: October 3, 2017Assignee: TARGOVAX ASAInventor: Jon Amund Eriksen
-
Patent number: 9775893Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.Type: GrantFiled: March 8, 2017Date of Patent: October 3, 2017Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
-
Patent number: 9775894Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.Type: GrantFiled: July 9, 2014Date of Patent: October 3, 2017Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATIONInventors: Michael J. Gale, Jr., Gretja Schnell, Yueh-Ming Loo
-
Patent number: 9775895Abstract: HIV neutralizing peptides, sulfated HIV-1 envelope proteins and immunogenic fragments thereof are disclosed, as well as nucleic acids encoding these molecules and methods of producing these peptides, envelope proteins and fragments. Methods are also provided for the treatment or prevention of a human immunodeficiency type 1 (HIV-1 ) infection. The methods can include administering to a subject an HIV neutralizing peptide, sulfated HIV-1 envelope protein or immunogenic fragment thereof as disclosed herein. In several embodiments, administering the HIV neutralizing peptide, sulfated HIV-1 envelope protein or immunogenic fragment generates an immune response in a subject.Type: GrantFiled: December 12, 2013Date of Patent: October 3, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Paolo Lusso, Raffaello Cimbro
-
Patent number: 9775896Abstract: The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.Type: GrantFiled: July 15, 2015Date of Patent: October 3, 2017Assignee: Qu Biologics Inc.Inventor: Harold David Gunn
-
Patent number: 9775897Abstract: Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.Type: GrantFiled: August 15, 2014Date of Patent: October 3, 2017Assignee: TAIGA BIOTECHNOLOGIES, INC.Inventors: Yosef Refaeli, Brian Curtis Turner
-
Patent number: 9775898Abstract: Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.Type: GrantFiled: February 24, 2016Date of Patent: October 3, 2017Assignee: TheVax Genetics Vaccine Co., Ltd.Inventors: Chia-Mao Wu, Jiun-Ming Wu, Yi-Tsui Chiu, Yin-Ching Lin, Hsien-Kai Chuang, Fu-Tan Hsieh, Kuan-Ming Chen
-
Patent number: 9775899Abstract: Methods of treating neuronal disorders, such as mechanical neuronal traumas and neurodegenerative disorders, with TWEAK or a TWEAK receptor blocking agents are presented.Type: GrantFiled: December 18, 2012Date of Patent: October 3, 2017Assignee: Biogen MA Inc.Inventors: Linda C. Burkly, Kyungmin Hahm, Timothy Zheng, Steve Perrin, John Lincecum
-
Patent number: 9775900Abstract: In the early detection of cancer, in particular bladder cancer, a photodynamic diagnosis uses, as a photosensitizer, a formulation that contains sodium hypericinate that is bonded to polyvinylpyrrolidone or complexed with polyvinylpyrrolidone.Type: GrantFiled: March 27, 2017Date of Patent: October 3, 2017Assignee: SANOCHEMIA PHARMAZEUTIKA AGInventors: Stefan Welzig, Beate Kälz, József Gungl, Klaus Gerdes, Werner Frantsits, Christina Abrahamsberg
-
Patent number: 9775901Abstract: Materials capable of delivering stabilized free radicals to targeted treatment sites. The materials comprise semi-crystalline, hydrolytically degradable polymers that are subjected to ionizing radiation to create stabilized free radicals therein. Upon exposure to oxygen containing aqueous media, the materials generate reactive oxidative species which are useful in biological processes.Type: GrantFiled: December 13, 2016Date of Patent: October 3, 2017Assignee: W.L. Gore & Associates, Inc.Inventors: Tiffany J. Brown, Adam S. Lafleur, Kenneth Mazich, Jeffrey C. Towler, Ji Zhang
-
Patent number: 9775902Abstract: The present invention relates to methods and agents useful for the treatment of stroke, including ischemic stroke and hemorrhagic stroke. In particular, methods and agents for treating stroke in a subject are provided, wherein the agent is administered prior to diagnosis of the stroke as an ischemic stroke or a hemorrhagic stroke.Type: GrantFiled: July 11, 2011Date of Patent: October 3, 2017Assignee: FIBROGEN, INCInventors: Stephen J. Klaus, Ingrid Langsetmo Parobok, Christopher T. Jacob
-
Patent number: 9775903Abstract: This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.Type: GrantFiled: January 13, 2011Date of Patent: October 3, 2017Assignees: JOHNS HOPKINS UNIVERSITY, OPKO IRELAND GLOBAL HOLDINGS, LTD.Inventors: Gary H. Posner, Lindsey C. Hess, Alvin S. Kalinda, Rachel D. Slack, Uttam Saha, P. Martin Petkovich
-
Patent number: 9775904Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.Type: GrantFiled: April 6, 2015Date of Patent: October 3, 2017Assignee: SANOFIInventors: Martin Bossart, Ralf Elvert, Andreas Evers, Torsten Haack, Siegfried Stengelin, Michael Wagner
-
Patent number: 9775905Abstract: An intrauterine device having at least one first pharmaceutically active ingredient and at least one first layer made of at least a first polymeric material, wherein between about 10 and about 60 v/v % of at least one particulate material is dispersed and/or incorporated in the first polymeric material. The presence of the particulate material will reduce the porosity of the polymer or otherwise obstruct the diffusion of the pharmaceutically active ingredient being released, thereby slowing its rate of release. In this way, it is possible to regulate the release rate and/or initial burst of the device, simply by adjusting the amount of particles/particulate material in the first layer, instead of having to adapt the size of the device to the desired release pattern, which requires expensive changes in production equipment and manufacturing processes.Type: GrantFiled: January 31, 2014Date of Patent: October 3, 2017Assignee: QPharma ABInventor: John Ingvar Feldtblad Kendrup
-
Patent number: 9775906Abstract: Some aspects of this disclosure relate to a method of treating an opthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreal site for controlled release of a therapeutic agent.Type: GrantFiled: June 16, 2009Date of Patent: October 3, 2017Assignee: Incept LLCInventors: Amarpreet S. Sawhney, William H. Ransone, II
-
Patent number: 9775907Abstract: Unpurified or low pure soy phosphatidylserine is used to make cochleates. The cochleates contain about 40-74% soy phosphatidylserine, a multivalent cation and a biological active. A preferred cochleate contains the antifungal agent amphotericin B.Type: GrantFiled: January 29, 2015Date of Patent: October 3, 2017Assignee: MATINAS BIOPHARMA NANOTECHNOLOGIES, INC.Inventors: Raphael Mannino, Ruying Lu
-
Patent number: 9775908Abstract: The subject of the present invention is a transdermal preparation containing pharmaceutically active ingredient, wherein the particles of the active ingredient are coated with highly volatile silicones or a mixture thereof, and these coated particles are dispersed in a gel or cream base. The volatile silicone component is hexamethyldisiloxane and/or octamethyltrisiloxane and/or decamethylpentacyclo-siloxane. A further subject of the present invention is a method for the preparation of such pharmaceutical compositions.Type: GrantFiled: July 10, 2008Date of Patent: October 3, 2017Assignee: EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAGInventors: Endre Mikulásik, Patrik Fazekas
-
Patent number: 9775909Abstract: The viscosity of aqueous dispersions of normally solid organic peroxides may be advantageously lowered through the use of surfactants which are polyglyceryl esters of C6-C12 fatty acids. The reduction in viscosity facilitates milling the peroxides to reduce particle size and also provides dispersions of small particle size peroxides which may be readily poured or pumped.Type: GrantFiled: March 1, 2013Date of Patent: October 3, 2017Assignee: Arkema Inc.Inventors: Thomas H. Kozel, Joseph M. Gravelle, Timothy Belford, Tomas Salvador
-
Patent number: 9775910Abstract: An aqueous suspension of a hydrophobic nutrient is disclosed. In particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension.Type: GrantFiled: July 22, 2014Date of Patent: October 3, 2017Assignee: Ingredient Innovations InternationalInventors: Christopher J Milley, Scott E Peters